Stock comparison
Halozyme Therapeutics
Teva Pharmaceutical Industries Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
TEVA
Teva Pharmaceutical Industries Limited
Market cap
$39.67B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | TEVA | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 46D | HALO |
| Benjamin Graham | 83A | 60D | HALO |
| Philip Fisher | 65B | 59C | HALO |
| Peter Lynch | 53D | 53C | Tie |
| Joel Greenblatt | 40D | 49D | TEVA |
| Charlie Munger | 80C | 50D | HALO |
| Terry Smith | 84A | 41D | HALO |
Side-by-side metrics
| Metric | HALO | TEVA |
|---|---|---|
| Market cap | $8.1B | $39.67B |
| P/E (TTM) | 24.0x | 25.4x |
| EV/EBIT | 10.2x | 24.8x |
| ROIC (TTM) | 23.65% | 11.49% |
| Gross margin | 81.24% | 51.98% |
| Net margin | 23.13% | 9.03% |
| Revenue CAGR 5y | 33.23% | 2.1% |
| EPS CAGR 5y | -1.98% | 34.13% |
| Debt / Equity | 1.0x | 2.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 2.1%+94%
- Net margin23.13%vs 9.03%+61%
- EV/EBIT10.2xvs 24.8x+59%
- Debt / Equity1.0xvs 2.1x+54%
TEVA leads on
- EPS CAGR 5y34.13%vs -1.98%+106%
- Market cap$39.67Bvs $8.1B+80%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.